Novonexile AG

Novonexile is developing Synmatrix, a flowable, resorbable hydrogel platform for the regeneration of bone and soft tissue. Upon application, the material solidifies in situ, offering significant procedural advantages in modern minimally invasive surgery. The patented platform is highly differentiated from existing graft formats and adaptable across a wide range of indicationsfrom oral surgery to orthopedics and cosmetic applications. Our goal is to build a globally scalable company rooted in Switzerland.